About 4 results found for searched term "Anti-human HER-2 mAb" (0.169 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M11384 | Anti-human HER-2 mAb | Recombinant Proteins |
| Biological activity: HER2, also known as ErbB2, is a member of the human epidermal growth factor receptor family and plays an important role in signal transduction. | ||
| M24828 | Trastuzumab deruxtecan | Drug-Linker Conjugates for ADC |
| DS-8201; DS-8201a | ||
| Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, and a topoisomerase I inhibitor. Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer. | ||
| M24941 | Disitamab vedotin | Drug-Linker Conjugates for ADC |
| RC48 | ||
| Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE). Disitamab vedotin enhances antitumor immunity. | ||
| M25096 | Anbenitamab | EGFR/HER2 |
| KN-026 | ||
| Anbenitamab (KN-026) is a bispecific antibody simultaneously targeting the extracellular domains II and IV of the human HER2. Anbenitamab blocks both ligand-dependent and ligand-independent HER2 signaling pathway. The IgG1 Fc fragment of Anbenitamab binds FcRγIIIa mediates potent antibody dependent cell-mediated cytotoxicity (ADCC) and inhibits tumor cell proliferation. Anbenitamab has the potential for HER2-positive metastatic breast cancer (MBC) research. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
